Access to data from clinical trials in the COVID-19 crisis: open, flexible, and time-sensitive

•Challenges of rapid COVID-19 drug development risk to compromise good scientific practice•Access to patient-level data especially urgent to address risks of protocol violations and rapid reviews.•Open access to data enables transparency, secondary analyses, and meta-analyses.•Politicization of scientific reports will be reduced by cross-checking and multilateral analyses.